SIOUX FALLS, S.D., June 06, 2022 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully human polyclonal antibodies without the need for human donors, today announced the appointment of Alexandra Kropotova, M.D., as Chief Medical Officer (CMO), to play a critical role in progressing SAB’s proprietary immune and autoimmune disorders pipeline.
SAB Biotherapeutics Announces Appointment of Alexandra Kropotova, M.D., as Chief Medical Officer
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
/Intel%20Corp_%20logo%20on%20mobile%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
/An%20image%20of%20a%20Tesla%20humanoid%20robot%20in%20front%20of%20the%20company%20logo%20Around%20the%20World%20Photos%20via%20Shutterstock.jpg)
/Alphabet%20(Google)%20Image%20by%20Markus%20Mainka%20via%20Shutterstock.jpg)
/Nvidia%20logo%20by%20Konstantin%20Savusia%20via%20Shutterstock.jpg)
